自身免疫性风湿病妊娠管理:前瞻性意大利P-RHEUM.it研究中母体病程、妊娠与新生儿结局及用药情况
意大利前瞻性队列P-RHEUM.it纳入29个风湿中心2018—2023年妊娠≤20周的866例自身免疫性风湿病孕妇,母体疾病 flare 135例(15.6%),活产794例(91.7%),并发症频率与意大利一般产科人群相似,作者认为孕前咨询与达标治疗可能有助于改善结局。
要点
- 866例妊娠中母体疾病 flare 135例(15.6%),活产794例(91.7%),84.9%为足月产。
- 产科并发症261例(30.1%),子痫前期2.3%;抗Ro/SSA妊娠157例中先天性心脏传导阻滞2例(1.3%)。
- 用药:糖皮质激素244例(28.2%)、羟氯喹388例(44.8%)、传统合成DMARDs 85例(9.8%)、生物DMARDs 122例(14.1%)。
核心结论
- 作者认为孕前咨询和使用妊娠 compatible 药物进行达标治疗等多种因素可能有助于减轻疾病相关危险因素,使疾病 flare 有限、妊娠结局良好且并发症频率与意大利一般产科人群相似。
- 作者指出需进一步处理疾病特异性问题以规划预防措施。
研究设计与样本
- 意大利前瞻性队列研究P-RHEUM.it,2018—2023年5年间在29个风湿中心纳入妊娠≤20周的不同自身免疫性风湿病孕妇。
- 共分析851例患者的866次妊娠,系统性红斑狼疮为最常见疾病(19.6%)。
- 母体与婴儿信息收集于网络数据库。
主要发现
- 母体疾病 flare 见于135次妊娠(15.6%),辅助生殖技术诱导妊娠53次(6.1%),流产61次(7%),选择性终止妊娠11次(1.3%)。
- 产科并发症261次妊娠(30.1%),其中子痫前期2.3%;抗Ro/SSA妊娠157次中先天性心脏传导阻滞2例(1.3%)。
- 活产794次(91.7%),大多足月(84.9%);围产期死亡4例(0.5%)。
- 790名新生儿中,小于胎龄儿31名(3.9%),围产期并发症169名(21.4%);纯母乳喂养404名(46.7%)。
- 爱丁堡产后抑郁量表由414名女性(52.4%)填写,89名(21.5%)情绪困扰筛查阳性。
关键数值与推荐
- 糖皮质激素治疗244次妊娠(28.2%),羟氯喹388次(44.8%),传统合成改善病情抗风湿药85次(9.8%),生物改善病情抗风湿药122次(14.1%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需进一步处理疾病特异性问题以规划预防措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate pregnancy outcomes in women with autoimmune rheumatic diseases (ARD) in the Italian prospective cohort study P-RHEUM.it. METHODS: Pregnant women with different ARD were enrolled for up to 20 gestational weeks in 29 Rheumatology Centres for 5 years (2018-2023). Maternal and infant information were collected in a web-based database. RESULTS: We analysed 866 pregnancies in 851 patients (systemic lupus erythematosus was the most represented disease, 19.6%). Maternal disease flares were observed in 135 (15.6%) pregnancies. 53 (6.1%) pregnancies were induced by assisted reproduction techniques, 61 (7%) ended in miscarriage and 11 (1.3%) underwent elective termination. Obstetrical complications occurred in 261 (30.1%) pregnancies, including 2.3% pre-eclampsia. Two cases of congenital heart block were observed out of 157 pregnancies (1.3%) with anti-Ro/SSA. Regarding treatments, 244 (28.2%) pregnancies were treated with glucocorticoids, 388 (44.8%) with hydroxychloroquine, 85 (9.8%) with conventional synthetic disease-modifying anti-rheumatic drugs and 122 (14.1%) with biological disease-modifying anti-rheumatic drugs. Live births were 794 (91.7%), mostly at term (84.9%); four perinatal deaths (0.5%) occurred. Among 790 newborns, 31 (3.9%) were small-for-gestational-age and 169 (21.4%) had perinatal complications. Exclusive maternal breast feeding was received by 404 (46.7%) neonates. The Edinburgh Postnatal Depression Scale was compiled by 414 women (52.4%); 89 (21.5%) scored positive for emotional distress. CONCLUSIONS: Multiple factors including preconception counselling and treat-to-target with pregnancy-compatible medications may have contributed to mitigate disease-related risk factors, yielding limited disease flares, good pregnancy outcomes and frequency of complications which were similar to the Italian general obstetric population. Disease-specific issues need to be further addressed to plan preventative measures.
引用
- Andreoli L, Gerardi MC, Gerosa M, et al. Management of pregnancy in autoimmune rheumatic diseases: maternal disease course, gestational and neonatal outcomes and use of medications in the prospectiveItalian P-RHEUM.it study. RMD Open. 2024. PMID: 38663885. doi:10.1136/rmdopen-2024-004091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。